CAMBRIDGE, Massachusetts — — Gen9, Inc., a pioneer in the development of scalable technologies for synthesizing and assembling DNA, today announced the launch of its Variant Libraries product, which allows customers to test virtually any number of DNA variant combinations and examine structure-function relationships. Initial applications include antibody or peptide engineering, and later versions of the product will enable enzyme engineering and pathway building.

Variant libraries are collections of synthetic DNA designed with targeted combinations of genetic variations. These libraries are used by scientists in biopharma and industrial engineering to identify antibodies for therapeutic and diagnostic applications and to optimize high-value industrial enzymes. With Gen9 Variant Libraries, customers can now accelerate their testing for DNA variant combinations to reach answers faster and more cost-effectively.

“The Gen9 BioFab process is especially suited for making highly diverse gene libraries. Our first offering will fulfill a need for rational design in the rapidly growing antibody engineering market,” said Chief Executive Officer Kevin Munnelly. “As our customers gain more insight into how to design and optimize antibodies, enzymes and even pathways using DNA sequencing and predictive informatics, Gen9 will continue making advances in how to produce these products.”

Gen9 Variant Libraries use rational design to ensure a bias-free, uniform distribution of variants and to greatly reduce the number of constructs that must be tested to find a successful combination. Gen9 is offering rationally designed combinatorial variant libraries, synthesized using its award-winning BioFab® process. These products are all based on Gen9’s proprietary next-gen gene synthesis technology, which includes error-correction protocols to remove unwanted substitutions and indels. All libraries are verified by sequencing and delivered as highly diverse pools.

Gen9 has developed unique, next-generation technologies for synthesizing and assembling DNA constructs for use in numerous synthetic biology applications. Today, Gen9 is manufacturing and shipping double-stranded GeneBit™, GeneByte™, and GeneByte Plus™ DNA constructs. The company’s innovative BioFab® platform has the capacity to generate tens of thousands of synthetic gene fragments per year in just a few square feet of laboratory space.

More information can be found at www.gen9bio.com.

About Gen9

Gen9 is synthesizing the future with its next-generation DNA manufacturing technologies. Founded by pioneers in the field of synthetic biology, Gen9 supplies synthetic DNA constructs to customers in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels. Through high-profile collaborations and extensive internal research and development, Gen9 is powering the synthetic biology revolution from its headquarters in Cambridge, Massachusetts, and can be found online at www.gen9bio.com.

Gen9, GeneBit, GeneByte, GeneByte Plus, and BioFab are trademarks or registered trademarks of Gen9, Inc. All other brands may be trademarks of their respective holders.